LMY-920 is under clinical development by Luminary Therapeutics and currently in Phase I for Non-Hodgkin Lymphoma. According to GlobalData, Phase I drugs for Non-Hodgkin Lymphoma have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how LMY-920’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LMY-920 is under development for the treatment of mantle cell lymphoma, scleroderma, relapsed and refractory multiple myeloma, non-Hodgkin lymphoma and acute lymphoblastic leukemia. The therapeutic candidate comprises of autologous T-cells that are genetically modified by transposon transduction to express chimeric antigen receptor (CAR) that targets B cell activating factor receptor (BAFF). It is being developed based on the Tcbuster technology.
It was also under development for Sjogren’s syndrome.
Luminary Therapeutics overview
Luminary Therapeutics is a cell therapy development company that discovers non-viral autologous treatments for cancer and autoimmune diseases. The company offers therapeutic solutions like Baff CAR-T immunotherapies, universal receptors that cells can multitask, non-viral allogeneic platform. It is investigating LMY-920, a non-viral CAR-T cell therapy targeting B-cell malignancies and autoimmune disorders, and LMY-232 to treat solid tumors and autoimmune diseases. The company seeks to work in partnership with key antibody companies to discover new chimeric antigen receptors (CAR’s). Luminary Therapeutics is headquartered in Minneapolis, Minnesota, the US.
For a complete picture of LMY-920’s drug-specific PTSR and LoA scores, buy the report here.